Pluri ROA

Que fait Pluri ? Pluri, Inc. develops cell therapies for critical limb ischemia, post-surgical femoral neck fracture recovery, and acute radiation syndrome. Its lead products PLX-PAD and PLX R18 utilize placental-derived stromal cells expanded through a 3D synthetic scaffold process. These adherent stromal cells are administered via standard needle and syringe for cardiovascular, orthopedic, pulmonary, and women's health indications. The company focuses on research, clinical trials, and manufacturing of cell therapeutics. The firm's PLX cells are grown in a 3D artificial environment using synthetic scaffolds, enabling scalable production of adherent stromal cells. PLX-PAD and PLX R18 are in clinical development for multiple therapeutic areas including cardiovascular, orthopedic, pulmonary, and women's health diseases. The company's operations span research, development, clinical trials, and manufacturing of cell-based treatments. Pluri, Inc. targets clinical-stage development for cell therapies with specific focus on critical limb ischemia, femoral neck fracture recovery, and acute radiation syndrome. Its products PLX-PAD and PLX R18 are designed for administration through standard medical delivery methods. The company's therapeutic portfolio covers cardiovascular, orthopedic, pulmonary, and women's health applications through its PLX cell technology platform. Pluri est l'une des entreprises les plus populaires sur Eulerpool.